This research study, known as the PARTNER 3 study, will evaluate the safety and effectiveness of transcatheter aortic valve replacement (TAVR) for severe aortic stenosis patients who are at low-risk for surgery.
TAVR is a less-invasive procedure than open heart surgery.
TAVR uses a catheter to implant a new valve within your diseased aortic valve.
The PARTNER 3 study is a randomized study. This means that you have a 50/50 chance of receiving either surgical aortic valve replacement or TAVR. Surgical aortic valve replacement is an open heart surgery. Most open heart surgeries are performed through an incision across the full length of the breast bone, or sternum.
Only professionals who have received extensive training are qualified to perform the TAVR procedure. A properly trained and dedicated, multidisciplinary Heart Team will conduct a thorough evaluation to determine if you may qualify for the study.
Edwards Lifesciences is the sponsor of this clinical research study.Am I Eligible?